

# Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors in Type 2 Diabetes: A Literature Review of Approved Products

Lucio R. Volino<sup>1,2</sup>, Eva Y. Pan<sup>1</sup>, Rupal Patel Mansukhani<sup>1,3</sup>

<sup>1</sup>Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, USA

<sup>2</sup>The Great Atlantic and Pacific Tea Company, Kenilworth, USA

<sup>3</sup>Morristown Medical Center, Morristown, USA

Email: [volinol@pharmacy.rutgers.edu](mailto:volinol@pharmacy.rutgers.edu)

Received 30 August 2014; revised 30 September 2014; accepted 16 October 2014

Copyright © 2014 by authors and Scientific Research Publishing Inc.

This work is licensed under the Creative Commons Attribution International License (CC BY).

<http://creativecommons.org/licenses/by/4.0/>



Open Access

---

## Abstract

Diabetes mellitus continues to be a major health issue worldwide. Despite all of the treatment options available on the market, many patients with diabetes fail to reach their treatment goals. Novel agents such as the Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors show promise in effectively lowering blood glucose. Objective: To review the scientific literature for efficacy information regarding the use of approved SGLT2 inhibitors (canagliflozin, dapagliflozin and empagliflozin) in the treatment of Type 2 Diabetes Mellitus (T2DM). Methods: A MEDLINE (1950-August 2014) literature review was performed. All of the literature published as an original clinical trial was included in this review. Other pertinent articles published related to the original clinical trial were also included. Meta-analysis type studies were not selected for this review. Conclusions: With an increasing prevalence and incidence of type 2 diabetes mellitus worldwide, there is an apparent need for effective therapeutic strategies to combat this chronic and progressive disease. SGLT2 inhibitors offer this potential. Recently approved agents (canagliflozin, dapagliflozin and empagliflozin) have shown significant promise as mono- and add-on therapy to current glucose-lowering regimens that may not otherwise be providing sufficient glycemic control in T2DM patients.

## Keywords

Canagliflozin, Dapagliflozin, SGLT2 Inhibitors, Type 2 Diabetes Mellitus, Empagliflozin

---

## 1. Introduction

Diabetes mellitus continues to be a major health issue worldwide, affecting nearly 26 million adults in the United States. Controlling blood glucose levels is essential in managing symptoms and preventing complications associated with the disease. In 2011, close to 85% of US adults with diabetes reported taking antihyperglycemic medication [1].


Despite all the treatment options available on the market, many patients with diabetes fail to reach their treatment goals. Most of these medications depend on the presence or action of insulin to exert their therapeutic effect. This can provide little benefit to patients whose disease progression has led to deterioration in pancreatic beta cell function. Additionally, these agents are associated with concerning side effects, including the risk of inducing hypoglycemia [2]-[4].

A new class of agents has emerged with glycemic control via alternate means, specifically by inhibiting the reabsorption of glucose and increasing its excretion from the kidneys. This novel approach of the Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors shows promise in effectively lowering blood glucose in a noninsulin-dependent way. Sodium-Glucose Cotransporter 2 inhibitors exert their effect by enhancing renal glycosuria. The extent to which they induce glycosuria is dependent on the plasma glucose concentration. As a result, blood glucose levels cannot be lowered below physiological levels and hence, the risk of hypoglycemia is not concerning [5]. This mechanism of action allows use as monotherapy or in combination with current antidiabetes medications, including insulin therapy [2]-[4]. Sodium-Glucose Cotransporter 2 inhibitors have also been shown to promote weight loss at the same time, either independently or in combination with other antidiabetic agents. However they have a risk of potentially increasing the likelihood of genitourinary tract infections [6].

The United States Food and Drug Administration (FDA) recently approved three SGLT2 inhibitors, canagliflozin in 2013, dapagliflozin and empagliflozin in 2014. This article discusses the SGLT2 inhibitors as new approaches to managing type 2 diabetes mellitus (T2DM), focusing on the evidence available regarding the efficacy and safety of this emerging class of antidiabetic agents. Canagliflozin, dapagliflozin, and empagliflozin were selected for this review since they are the only agents currently approved by the FDA.

## 2. Data Sources

**Figure 1** illustrates the literature search and selection process details used in the identification of clinical trials for this review. A literature review was performed in MEDLINE (1950-August 2014) using the keywords diabetes mellitus type 2 AND canagliflozin OR dapagliflozin OR empagliflozin. The references identified from the literature review were then evaluated. All of the literature retrieved from MEDLINE that was published as an original clinical trial was included in this review. Other pertinent articles published related to the original clinical trials were also considered. Meta-analysis type studies were not selected for this review. References included in this review were limited to studies conducted in humans and written in the English language.



**Figure 1.** Literature search and clinical trial selection details.

### 3. SGLT2 Product Review Summaries

#### 3.1. Canagliflozin

Canagliflozin, (1S)-1,5-anhydro-1-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol hemihydrate, the first SGLT2 inhibitor approved in the United States, has an oral bioavailability of 65%, which remains the same with or without food. However, it is recommended to be taken before the first meal of the day due to its mechanism of reducing postprandial glucose excursions. Peak plasma concentrations are reached within one to two hours post-dose with a terminal half-life of 10.6 hours and 13.1 hours for the respective 100 mg and 300 mg doses. Canagliflozin exhibits extensive protein binding (99%), mainly to albumin, which does not affect plasma concentrations. It is metabolized primarily through *O*-glucuronidation and marginally through CYP3A4 (7%), and is excreted through fecal and renal routes. Though renal impairment may lead to a change in maximum plasma concentration ( $C_{\max}$ ) and area under the curve (AUC), these changes are not clinically relevant. However, since canagliflozin works by reducing glucose reabsorption in the kidney, pharmacodynamic response to the drug declines as the severity of renal impairment increases. Therefore, it is contraindicated in severe renal impairment, end stage renal disease, or patients on dialysis. According to Child-Pugh class grading, mild and moderate hepatic impairment do not warrant dose adjustments with canagliflozin [4].

The efficacy of canagliflozin was studied in ten trials ranging from 12 to 52 weeks and at doses of 50 mg, 100 mg, 200 mg, and 300 mg (Table 1) [7]-[16]. The greatest difference in hemoglobin A1C (HbA1C) (%) reduction compared to placebo was -1.16% with canagliflozin 300 mg after 26 weeks [13]. Eight out of ten studies reported that HbA1C (%) reductions were statistically significant [7] [8] [10] [11] [13]-[16]. All ten trials found that a greater percentage of patients reached the HbA1C (%) goal of <7.0% with canagliflozin treatment than with other treatments [7]-[16]. The majority of these studies also reported a statistically significant difference [7] [8] [11] [13] [14] [16].

Reductions in 2-hour postprandial glucose (2-h PPG) [10]-[14] and fasting plasma glucose (FPG) [7]-[16] were also greater in canagliflozin groups, with mean decreases in FPG ranging from -38.3 mg/dL [10] to -11.7 mg/dL [15] in two different canagliflozin 300 mg groups. Since other oral antidiabetic agents are often associated with weight gain, studies also assessed the change in body weight with canagliflozin. Most studies showed a statistically significant difference with lowering body weight in the canagliflozin groups compared to other treatment groups [7]-[14] [16]. Some evidence shows a slight, yet significant reduction in systolic blood pressure by canagliflozin compared to placebo (reduction of range of -8.1 to -3.5 mmHg) [8] [10] [13] [16] and sitagliptin (reduction range of -5.9 to -2.9 mmHg) [11] [12].

The overall incidence of adverse events was similar between canagliflozin and control group treatment, however more patients withdrew related to canagliflozin adverse events. Since the SGLT2 inhibitors work by increasing the amount of glucose in the urine, there is a risk of urinary and genital tract infections unique to this class. Adverse events such as pollakiuria, polyuria, and volume-related effects, including postural dizziness and orthostatic hypotension, were more common in canagliflozin groups [7]-[16].

As expected, based on the mechanism of action of SGLT2 inhibitors, the majority of studies reported low incidences of hypoglycemia in canagliflozin groups which were similar to sitagliptin [11] [12] [16] and placebo [7] [8] [10] [13] [16] groups. Canagliflozin was reported to have higher rates of hypoglycemia compared to placebo when combined with other hypoglycemia-associated medications such as insulin [15] or a sulfonylurea [14] [15]. Hypoglycemia occurred significantly less in canagliflozin groups (5% - 6%) compared to the glimepiride treatment group (34%) [9].

#### 3.2. Dapagliflozin

Dapagliflozin, D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1S)-, compounded with (2S)-1,2-propanediol, hydrate (1:1:1) [2], was rejected by the FDA in January 2012 due to concerns about the cancer risk seen in studies [17]. However, after reviewing more data on its safety profile, dapagliflozin was approved by the FDA in early 2014. The pharmacokinetic and pharmacodynamic properties of dapagliflozin are similar to canagliflozin. Dapagliflozin can be administered without regard to food. The oral bioavailability of dapagliflozin 10 mg is 78%. Maximum plasma concentration is usually reached within two hours in a fasting state and administration with a high-fat meal decreases the  $C_{\max}$  by up to 50% without altering the AUC, but is not clinically significant. The terminal half-life is approximately 12.9 hours following a dose of 10 mg. Dapag-

**Table 1.** Canagliflozin trials.

Author (Year)	Study Design	Subjects	Methods	Results								
				HbA1C (%) at 12 Weeks								
				Baseline Mean ± SD	LS Mean Change	Difference vs. PBO						
Rosenstock (2012)	Randomized Double-blind Placebo-controlled Parallel-group	451 T2DM (236M; 215F)	(Stable dose of MET ≥ 3 months)  Pre-treatment Screening Period: 3 - 4 weeks  Double-Blind Treatment Period: 12 weeks  Group A: placebo daily  Group B: CANA 50 mg daily  Group C: CANA 100 mg daily  Group D: CANA 200 mg daily  Group E: CANA 300 mg once daily  Group F: CANA 300 mg twice daily  Group G: SITA 100 mg daily  Post-treatment Period: 2 weeks	PBO (N = 65)	7.75 ± 0.83	-0.22	-					
				CANA 50 mg (N = 64)	8.00 ± 0.99	-0.79*	-					
				CANA 100 mg (N = 64)	7.83 ± 0.96	-0.76*	-					
				CANA 200 mg (N = 65)	7.61 ± 0.80	-0.70*	-					
				CANA 300 mg QD (N = 64)	7.69 ± 1.02	-0.92*	-					
				CANA 300 mg BID (N = 64)	7.73 ± 0.89	-0.95*	-					
				SITA 100 mg	7.64 ± 0.95	-0.74*	-					
								*p < 0.001 vs. PBO				
								FPG (mg/dL) at 12 Weeks				
								Baseline Mean ± SD	LS Mean Change	Difference vs. PBO		
								PBO (N = 65)	164 ± 38	3.6	-	
								CANA 50 mg (N = 64)	170 ± 45	-16.2*	-	
								CANA 100 mg (N = 64)	168 ± 42	-25.2*	-	
								CANA 200 mg (N = 65)	160 ± 37	-27.0*	-	
								CANA 300 mg QD (N = 64)	159 ± 44	-25.2*	-	
								CANA 300 mg BID (N = 64)	157 ± 34	-23.4*	-	
								SITA 100 mg	158 ± 42	-12.6	-	
				*p < 0.001 vs. PBO								
				Body Weight (kg) at 12 Weeks								
				Baseline Mean ± SD	LS Mean Percent Change	Difference vs. PBO						
				PBO (N = 65)	85.9 ± 19.5	-1.1	-					
				CANA 50 mg (N = 64)	87.6 ± 16.3	-2.3*	-					
				CANA 100 mg (N = 64)	87.7 ± 15.5	-2.6*	-					
				CANA 200 mg (N = 65)	87.7 ± 17.0	-2.7*	-					
				CANA 300 mg QD (N = 64)	87.3 ± 15.9	-3.4*	-					
				CANA 300 mg BID (N = 64)	86.0 ± 19.7	-3.4*	-					
				SITA 100 mg	87.2 ± 18.0	-0.6	-					
				*p < 0.001 vs. PBO								

Continued

			HbA1C (%) at 26 Weeks			
			Baseline Mean ± SD	Adjusted Mean Change	Difference vs. PBO	
			PBO (N = 237)	7.8 ± 0.8	-0.03	-
			CANA 100 mg (N = 241)	7.8 ± 0.8	-0.6	-0.57*
			CANA 300 mg (N = 236)	7.7 ± 0.8	-0.73	-0.70*
Single-blind, Placebo Run-in Period: 2 weeks			*p < 0.001 vs. PBO			
			FPG (mg/dL) at 26 Weeks			
			Baseline Mean ± SD	Adjusted Mean Change	Difference vs. PBO	
Double-blind Core Treatment Period: 26 weeks						
Group A: placebo daily before first meal of day			PBO (N = 237)	156.8 ± 38.9	7.4	-
Group B: CANA 100 mg daily before first meal of day			CANA 100 mg (N = 241)	160.4 ± 38.7	-18.1	-25.5*
Group C: CANA 300 mg daily before first meal of day			CANA 300 mg (N = 236)	153.2 ± 36.6	-20.3	-27.7*
			*p < 0.001 vs. PBO			
			Body Weight (kg) at 26 Weeks			
			Baseline Mean ± SD	Adjusted Mean Percent Change	Difference vs. PBO	
Double-blind Extension Period: 78 weeks						
			PBO (N = 237)	91.1 ± 17.5	0.1	-
			CANA 100 mg (N = 241)	88.4 ± 15.6	-2.4	-2.3*
			CANA 300 mg (N = 236)	88.8 ± 17.1	-3.1	-3.0*
			*p < 0.001 vs. PBO			
			HbA1C (%) at 52 Weeks			
Single-Blind Run-in Period: 2 weeks			Baseline Mean ± SD	LS Mean Change ± SE	Difference vs. GLIM (95% CI)	
Study Phase: 52 weeks						
All groups on stable daily metformin dose for at least 10 weeks plus			GLIM (N = 482)	7.8 ± 0.8	-0.81 ± 0.04	-
			CANA 100 mg (N = 483)	7.8 ± 0.8	-0.82 ± 0.04	-0.01 (-0.11, 0.09)
Group A: GLIM 1 - 6 mg or 1 - 8 mg daily (based on maximum approved dose in country of investigational site)			CANA 300 mg (N = 485)	7.8 ± 0.8	-0.93 ± 0.04	-0.12 (-0.22, -0.02)
			FPG (mg/dL) at 52 Weeks			
			Baseline Mean ± SD	LS Mean Change	Difference vs. GLIM (95% CI)	
Group B: CANA 100 mg daily			GLIM (N = 482)	165.8 ± 37.8	-18.4	-
Group C: CANA 300 mg daily			CANA 100 mg (N = 483)	165.8 ± 37.8	-24.3	-5.9 (-10.8, -1.8)
Double-blind Extension Period: 52 weeks			CANA 300 mg (N = 485)	164.0 ± 36.0	-27.4	-9.2 (-12.6, -5.4)
Bode (2013)	Randomized Double-blind Placebo- controlled	714 T2DM with (396M; 318F)				
Cefalu (2013)	Randomized Double-blind Active- controlled Non- inferiority	1450 T2DM (756M; 694F)				

Continued

				Body Weight (kg) at 52 Weeks				
				Baseline Mean ± SD	LS Mean Percentage Change ± SE	Difference vs. GLIM (95% CI)		
				GLIM (N = 482)	86.5 ± 19.8	1.0 ± 0.2	-	
				CANA 100 mg (N = 483)	86.9 ± 20.1	-4.2 ± 0.2	-5.2* (-5.7, -4.7)	
				CANA 300 mg (N = 485)	86.6 ± 19.5	-4.7 ± 0.2	-5.7* (-6.2, -5.1)	
				*p < 0.0001 vs. GLIM				
				HbA1C (%) at 12 Weeks				
				Baseline Mean ± SD	Adjusted Mean Change	Difference vs. PBO		
				PBO (N = 75)	7.99 ± 0.77	0.11	-	
				CANA 50 mg (N = 82)	8.13 ± 0.78	-0.61*	-	
				CANA 100 mg (N = 74)	8.05 ± 0.86	-0.80 <sup>††</sup>	-	
				CANA 200 mg (N = 76)	8.11 ± 0.88	-0.79 <sup>††</sup>	-	
				CANA 300 mg (N = 75)	8.17 ± 0.81	-0.88 <sup>††</sup>	-	
				*p < 0.01 vs. PBO				
				†p < 0.05 vs. CANA 50 mg				
				FPG (mg/dL) at 12 Weeks				
				Baseline Mean ± SD	Adjusted Mean Change	Difference vs. PBO		
				PBO (N = 75)	170.7 ± 31.9	-3	-	
				CANA 50 mg (N = 82)	161.4 ± 34.6	-24.7*	-	
				CANA 100 mg (N = 74)	161.0 ± 32.1	-33.1 <sup>††</sup>	-	
				CANA 200 mg (N = 76)	165.9 ± 31.4	-36.1 <sup>††</sup>	-	
				CANA 300 mg (N = 75)	169.1 ± 34.2	-38.3 <sup>††</sup>	-	
				*p < 0.01 vs. PBO				
				†p < 0.01 vs. CANA 50 mg				
				Body Weight (kg) at 12 Weeks				
				Baseline Mean ± SD	Adjusted Mean Change	Difference vs. PBO		
				PBO (N = 75)	72.56 ± 15.36	-0.78	-	
				CANA 50 mg (N = 82)	65.77 ± 13.56	-1.98*	-	
				CANA 100 mg (N = 74)	68.61 ± 14.86	-2.51*	-	
				CANA 200 mg (N = 76)	68.97 ± 14.50	-2.39*	-	
				CANA 300 mg (N = 75)	71.30 ± 12.19	-3.19*	-	
				*p < 0.01 vs. PBO				

Inagaki (2013)

Randomized Double-blind Placebo-controlled

382 T2DM (260M; 122F)

Double-Blind Treatment Period: 12 weeks

Group A: placebo daily

Group B: CANA 50 mg daily

Group C: CANA 100 mg daily

Group D: CANA 200 mg daily

Group E: CANA 300 mg daily

Follow-up Visit: 2 weeks

Washout Period: 8 weeks  
Single-blind Run-in Period: 4 weeks

Continued

			HbA1C (%) at 26 Weeks						
			Baseline Mean $\pm$ SD	LS Mean Change $\pm$ SE	Difference vs. PBO (95% CI)				
Lavalle-González (2013)	Randomized Double-blind Parallel-group Placebo- and Active-controlled	1284 T2DM (605M; 679F)	PBO (N = 183)	8.0 $\pm$ 0.9	-0.17 $\pm$ 0.06	-			
			SITA 100 mg (N = 366)	7.9 $\pm$ 0.9	-0.82 $\pm$ 0.04	-0.66 <sup>†</sup> (-0.80, -0.52)			
			CANA 100 mg (N = 368)	7.9 $\pm$ 0.9	-0.79 $\pm$ 0.04	-0.62 <sup>*</sup> (-0.76, -0.48)			
			CANA 300 mg (N = 367)	7.9 $\pm$ 0.9	-0.94 $\pm$ 0.04	-0.77 <sup>*</sup> (-0.91, -0.64)			
			MET and SU Dose Titration/Stabilization/Washout Period: up to 10 weeks (if applicable)			* p < 0.001 vs. PBO			
			†Statistical comparison vs. PBO not performed (not pre-specified)						
			Single-blind, Placebo Run-in Period: 2 weeks			FPG (mg/dL) at 26 Weeks			
			Double-blind, Placebo- and Active-controlled Treatment Period I: 26 weeks			Baseline Mean $\pm$ SD	LS Mean Change $\pm$ SE	Difference vs. PBO (95% CI)	
			Group A: placebo daily			PBO (N = 183)	164.0 $\pm$ 37.8	1.8 $\pm$ 1.8	-
			Group B: SITA 100 mg daily			SITA 100 mg (N = 366)	169.4 $\pm$ 41.4	-19.8 $\pm$ 1.8	-23.4 <sup>†</sup> (-28.8, -16.2)
			Group C: CANA 100 mg daily			CANA 100 mg (N = 368)	167.6 $\pm$ 41.4	-27.0 $\pm$ 1.8	-30.6 <sup>*</sup> (-36.0, -23.4)
			Group D: CANA 300 mg daily			CANA 300 mg (N = 367)	173.0 $\pm$ 45.0	-37.8 $\pm$ 1.8	-39.6 <sup>*</sup> (-46.8, -34.2)
†Statistical comparison vs. PBO not performed (not pre-specified)			* p < 0.001 vs. PBO						
Double-blind, Active-controlled Treatment Period II: 26 weeks (Groups B-D remained the same. Group A (placebo) switched to SITA 100 mg daily)			Body Weight (kg) at 26 Weeks						
Follow-up Period: 4 weeks			Baseline Mean $\pm$ SD	LS Mean Percent Change $\pm$ SE	Difference vs. PBO (95% CI)				
PBO (N = 183)			86.6 $\pm$ 22.4	-1.2 $\pm$ 0.3	-				
SITA 100 mg (N = 366)			87.7 $\pm$ 21.6	-1.2 $\pm$ 0.2	0.0 <sup>†</sup> (-0.6, 0.6)				
CANA 100 mg (N = 368)			88.8 $\pm$ 22.2	-3.7 $\pm$ 0.2	-2.5 <sup>*</sup> (-3.1, -1.9)				
CANA 300 mg (N = 367)			85.4 $\pm$ 20.9	-4.2 $\pm$ 0.2	-2.9 <sup>*</sup> (-3.5, -2.3)				
* p < 0.001 vs. PBO			†Statistical comparison vs. PBO not performed (not pre-specified)						
			HbA1C (%) at 52 Weeks						
			Baseline Mean $\pm$ SD	LS Mean Change $\pm$ SE	Difference vs. SITA (95% CI)				
SITA 100 mg (N = 366)			7.9 $\pm$ 0.9	-0.73 $\pm$ 0.05	-				
CANA 100 mg (N = 368)			7.9 $\pm$ 0.9	-0.73 $\pm$ 0.05	0.00 (-0.12, 0.12)				

Continued

				CANA 300 mg (N = 367)	7.9 ± 0.9	-0.88 ± 0.05	-0.15 (-0.27, -0.03)
				FPG (mg/dL) at 52 Weeks			
					Baseline Mean ± SD	LS Mean Change ± SE	Difference vs. SITA (95% CI)
				SITA 100 mg (N = 366)	167.6 ± 41.4	-18.0 ± 1.8	-
				CANA 100 mg (N = 368)	169.4 ± 41.4	-27.0 ± 1.8	-9.0* (-12.6, -3.6)
				CANA 300 mg (N = 367)	173.0 ± 45.0	-36.0 ± 1.8	-18.0* (-21.6, -12.6)
				*p < 0.001 vs. SITA			
				Body Weight (kg) at 52 Weeks			
					Baseline Mean ± SD	LS Mean Percent Change ± SE	Difference vs. SITA (95% CI)
				SITA 100 mg (N = 355)	87.7 ± 21.6	-1.3 ± 0.2	-
				CANA 100 mg (N = 365)	88.8 ± 22.2	-3.8 ± 0.2	-2.4* (-3.0, -1.8)
				CANA 300 mg (N = 360)	85.4 ± 20.9	-4.2 ± 0.2	-2.9* (-3.4, -2.3)
				*p < 0.001 vs. SITA			
				HbA1C (%) at 52 Weeks			
					Baseline Mean ± SD	LS Mean Change	Difference vs. SITA (95% CI)
				SITA 100 mg (N = 378)	8.1 ± 0.9	-0.66	-
				CANA 300 mg (N = 377)	8.1 ± 0.9	-1.03	-0.37 (-0.50, -0.25)
				FPG (mg/dL) at 52 Weeks			
					Baseline Mean	LS Mean Change	Difference vs. SITA
				SITA 100 mg (N = 378)	165.8 ± 44.9	-5.9	-
				CANA 300 mg (N = 377)	169.4 ± 42.4	-29.9	-24.1*
				*p < 0.001 vs. SITA			
				Body Weight (kg) at 52 Weeks			
					Baseline Mean	LS Mean Percent Change	Difference vs. SITA (95% CI)
				SITA (N = 378)	89.1 ± 23.2	0.3	-
				CANA 300 mg (N = 377)	87.4 ± 23.2	-2.5	-2.8*
				*p < 0.001 vs. SITA			
Scherthaner (2013)	Randomized Double-blind Active-controlled	755 T2DM (422M; 333F)	MET and SU Adjustment Period (if applicable): up to 12 weeks (Including an 8-week dose-stable period) Single-blind, Placebo Run-in Period: 2 weeks Double-blind Treatment Period: 52 weeks Group A: SITA 100 mg daily Group B: CANA 300 mg daily Follow-up Period: 4 weeks				



## Continued

			HbA1C (%) at 26 Weeks					
			Baseline Mean $\pm$ SD	LS Mean Percent Change	Difference vs. PBO (95% CI)			
Stenlöf (2013)	Randomized Double-blind Placebo-controlled	584 T2DM (258M; 326F)	Single-blind Placebo Run-in period: 2 weeks	PBO (N = 192)	8.0 $\pm$ 1.0	0.14	-	
				CANA 100 mg (N = 195)	8.1 $\pm$ 1.0	-0.77	-0.91* (-1.1, -0.7)	
				CANA 300 mg (N = 197)	8.0 $\pm$ 1.0	-1.03	-1.16* (-1.3, -1.0)	
				*p < 0.001 vs. PBO				
				FPG (mg/dL) at 26 Weeks				
				Baseline Mean $\pm$ SD				LS Mean Change
		Double-blind, Placebo-controlled Treatment Period: 26 weeks	PBO (N = 192)	167.6 $\pm$ 37.8	9	-		
			Group A: placebo daily	CANA 100 mg (N = 195)	173.0 $\pm$ 43.2	-27	-36.0* (-41.4, -28.8)	
			Group B: CANA 100 mg daily	CANA 300 mg (N = 197)	173.0 $\pm$ 43.2	-34.2	-43.2* (-50.5, -36.0)	
			Group C: CANA 300 mg daily	*p < 0.001 vs. PBO				
			Body Weight (kg) at 26 Weeks					
			Baseline Mean $\pm$ SD				LS Mean Percent Change	Difference vs. PBO (95% CI)
Double-blind Extension Period: 26 weeks	PBO (N = 192)	87.6 $\pm$ 19.5	-0.6	-				
	CANA 100 mg (N = 195)	85.8 $\pm$ 21.4	-2.8	-2.2* (-2.9, -1.6)				
	CANA 300 mg (N = 197)	86.9 $\pm$ 20.5	-3.9	-3.3* (-4.0, -2.6)				
	*p < 0.001 vs. PBO							
	HbA1C (%) at 26 Weeks							
	Baseline Mean $\pm$ SD				LS Mean Change	Difference vs. PBO (95% CI)		
Wilding (2013)	Randomized Double-blind Placebo-controlled	469 T2DM (239M; 230F)	MET and SU Maximum Effective Dose Pretreatment Period: up to 12 weeks (dose titration up to 4 weeks; stable dose for 8 weeks)	PBO (N = 156)	8.1 $\pm$ 0.9	-0.13	-	
				CANA 100 mg (N = 157)	8.1 $\pm$ 0.9	-0.85	-0.71* (-0.90, -0.52)	
				CANA 300 mg (N = 156)	8.1 $\pm$ 0.9	-1.06	-0.92* (-1.11, -0.73)	
				*p < 0.001 vs. PBO				
				FPG (mg/dL) at 26 Weeks				
				Baseline Mean $\pm$ SD				LS Mean Change
		Single-blind, Placebo Run-in Period: 2 weeks	PBO (N = 156)	169.4 $\pm$ 39.6	3.6	-		
			Group A: placebo daily before first meal	CANA 100 mg (N = 157)	173.0 $\pm$ 41.4	-18	-21.6* (-30.6, -12.6)	
			Group B: CANA 100 mg daily before first meal	CANA 300 mg (N = 156)	167.6 $\pm$ 37.8	-30.6	-34.2* (-43.2, -25.2)	
			Group C: CANA 300 mg daily before first meal	*p < 0.001 vs. PBO				
			Double-blind Extension Period: 26 weeks					
			Baseline Mean $\pm$ SD				LS Mean Change	Difference vs. PBO (95% CI)

Continued

				*p < 0.001 vs. PBO				
				Body Weight (kg) at 26 Weeks				
				Baseline Mean ± SD	LS Mean Percent Change	Difference vs. PBO (95% CI)		
				PBO (N = 156)	91.2 ± 22.6	-0.7	-	
				CANA 100 mg (N = 157)	93.8 ± 22.6	-2.1	-1.4* (-2.1, -0.7)	
				CANA 300 mg (N = 156)	93.5 ± 22.0	-2.6	-2.0* (-2.7, -1.3)	
				*p < 0.001 vs. PBO				
				HbA1C (%) at 52 Weeks				
				Baseline Mean ± SD	LS Mean Change	Difference vs. PBO (95% CI)		
				PBO (N = 156)	8.1 ± 0.9	0.01	-	
				CANA 100 mg (N = 157)	8.1 ± 0.9	-0.74	-0.75 (-0.95, -0.55)	
				CANA 300 mg (N = 156)	8.1 ± 0.9	-0.96	-0.97 (-1.17, -0.77)	
				FPG (mg/dL) at 52 Weeks				
				Baseline Mean ± SD	LS Mean Change	Difference vs. PBO (95% CI)		
				PBO (N = 156)	169.4 ± 39.6	10.8	-	
				CANA 100 mg (N = 157)	173.0 ± 41.4	-19.8	-28.8 (-37.8, -19.8)	
				CANA 300 mg (N = 156)	167.6 ± 37.8	-27	-37.8 (-46.8, -28.8)	
				Body Weight (kg) at 52 Weeks				
				Baseline Mean ± SD	LS Mean Percent Change	Difference vs. PBO (95% CI)		
				PBO (N = 156)	91.2 ± 22.6	-0.9	-	
				CANA 100 mg (N = 157)	93.8 ± 22.6	-2.2	-1.3 (-2.1, -0.5)	
				CANA 300 mg (N = 156)	93.5 ± 22.0	-3.2	-2.2 (-3.0, -1.4)	
				HbA1C (%) at 26 Weeks				
				Baseline Mean ± SD	LS Mean Change	Difference vs. PBO (95% CI)		
Yale (2013)	Randomized Double-blind Placebo-controlled	269 T2DM with chronic kidney disease (163M; 106F)	AHA Dose Titration Period (if required): up to 4 weeks	PBO (N = 90)	8.0 ± 0.9	-0.03	-	
			AHA Dose Stable Period (if required): 8 weeks	CANA 100 mg (N = 90)	7.9 ± 0.9	-0.33	-0.30* (-0.5, -0.1)	
			Single-blind, Placebo Run-in Period: 2 weeks	CANA 300 mg (N = 89)	8.0 ± 0.8	-0.44	-0.40** (-0.6, -0.2)	
			Double-blind Core Treatment Period: 26 weeks					
Group A: placebo daily				*p < 0.05 vs. PBO				
				**p < 0.001 vs. PBO				

Continued

			FPG (mg/dL) at 26 Weeks			
			Baseline Mean ± SD	LS Mean Change	Difference vs. PBO (95% CI)	
			PBO (N = 90)	160.4 ± 43.2	0.5	-
			CANA 100 mg (N = 90)	169.4 ± 46.3	-14.9	-15.4 <sup>†</sup> (-28.5, -2.3)
			CANA 300 mg (N = 89)	158.6 ± 58.0	-11.7	-12.2 <sup>*</sup> (-25.4, 1.0)
Group B: CANA 100 mg daily			*p = NS for CANA vs. PBO			
Group C: CANA 300 mg daily			†Statistical comparison vs. PBO not performed owing to multiplicity control			
			Body Weight (kg) at 26 Weeks			
			Baseline Mean ± SD	LS Mean Percent Change	Difference vs. PBO (95% CI)	
			PBO (N = 90)	92.8 ± 17.4	0.3	-
			CANA 100 mg (N = 90)	90.5 ± 18.4	-1.2	-1.6 <sup>†</sup> (-2.3, -0.8)
			CANA 300 mg (N = 89)	90.2 ± 18.1	-1.5	-1.8 <sup>†</sup> (-2.6, -1.0)
Double-blind Extension Period: 26 weeks			†Statistical comparison for CANA vs. PBO not performed (not prespecified)			
			HbA1C (%) at 26 Weeks			
			Baseline Mean ± SD	LS Mean Change	Difference vs. PBO	
Single-blind, Placebo Run-in Period: 2 weeks			PBO/SITA (N = 115)	8.0 ± 1.0	-0.26	-
Double-blind, Placebo-Controlled Core Treatment Period: 26 weeks			CANA 100 mg (N = 113)	8.0 ± 0.9	-0.89	-0.62 <sup>*</sup>
			CANA 300 mg (N = 114)	7.9 ± 0.9	-1.03	-0.76 <sup>*</sup>
Group A: placebo daily			*p < 0.001 vs. PBO			
			FPG (mg/dL) at 26 Weeks			
			Baseline Mean	LS Mean Change	Difference vs. PBO	
Group B: CANA 100 mg daily			PBO/SITA (N = 115)	164.0 ± 39.6	2.5	-
			CANA 100 mg (N = 113)	169.4 ± 39.6	-26.8	-29.4 <sup>*</sup>
Double-blind Active-control Extension Period: 26 weeks			CANA 300 mg (N = 114)	164.0 ± 41.4	-33.2	-35.7 <sup>*</sup>
Group A: SITA 100 mg daily			*p < 0.001 vs. PBO			
			Body Weight (kg) at 26 Weeks			
			Baseline Mean ± SD	LS Mean Percent Change	Difference vs. PBO	
Group B: CANA 100 mg daily			PBO/SITA (N = 115)	93.8 ± 22.4	-0.1	-
Group C: CANA 300 mg daily			CANA 100 mg (N = 113)	94.2 ± 22.2	-2.8	-2.7 <sup>*</sup>

Forst (2014)

Randomized Double-blind Placebo- and Active-controlled

342 T2DM (216M; 126F)

## Continued

CANA 300 mg (N = 114)	94.4 ± 25.9	-3.8	-3.7*
* p < 0.001 vs. PBO			
HbA1C (%) at 52 Weeks			
	Baseline Mean ± SD	LS Mean Change (95% CI)	LS Mean Change (95% CI)
PBO/SITA (N = 115)	8.0 ± 1.0	-	-
CANA 100 mg (N = 113)	8.0 ± 0.9	-0.92 (-1.06, -0.79)	-
CANA 300 mg (N = 114)	7.9 ± 0.9	-1.03 (-1.17, -0.89)	-
FPG (mg/dL) at 52 Weeks			
	Baseline Mean	LS Mean Change (95% CI)	Difference vs. PBO
PBO/SITA (N = 115)	164.0 ± 39.6	-	-
CANA 100 mg (N = 113)	169.4 ± 39.6	-26.7 (-32.4, -21.1)	-
CANA 300 mg (N = 114)	164.0 ± 41.4	-31.5 (-37.2, -25.8)	-
Body Weight (kg) at 52 Weeks			
	Baseline Mean	LS Mean Percent Change (95% CI)	Difference vs. PBO
PBO/SITA (N = 115)	93.8 ± 22.4	-	-
CANA 100 mg (N = 113)	94.2 ± 22.2	-2.7 (-3.6, -1.9)	-
CANA 300 mg (N = 114)	94.4 ± 25.9	-3.7 (-4.6, -2.9)	-

95% CI = 95% confidence interval; AHA = antihyperglycemic agent; AM = morning; CANA = canagliflozin; F = Female; FPG = Fasting Plasma Glucose; GLIM = glimepiride; HbA1C = hemoglobin A1C; LS = least squares; M = Male; MET = metformin; NS = not significant; PBO = placebo; SD = standard deviation; SE = standard error; SITA = sitagliptin; SU = sulfonylurea; T2DM = Type 2 Diabetes Mellitus Patients

liflozin is 91% protein bound, which is unchanged in patients with renal or hepatic impairment. It is metabolized primarily by UGT1A9 with minor CYP-activity and is eliminated mainly through the kidneys. At steady state, T2DM patients with mild, moderate, or severe renal impairment (determined by estimated glomerular filtration rate (eGFR)) experience 45% to 3-fold higher systemic exposure of the drug without a corresponding higher 24-hour urinary glucose excretion. The steady state 24-hour urinary glucose excretion is 42% - 90% lower in these patients [2].

Dapagliflozin is not recommended in patients with moderate renal impairment as improvement in glycemic control was not seen in this population. Additionally, dapagliflozin is not expected to be effective in patients with severe renal impairment or end stage renal disease (ESRD). Dapagliflozin is contraindicated in these populations along with patients on dialysis. According to Child-Pugh class grading, mild, moderate, and severe hepatic impairment do not warrant dose adjustments with dapagliflozin, but the risk-benefit for use in patients with severe impairment should be individually assessed as the safety and efficacy have not been specifically studied in this population [2].

Overall, 11 studies assessing the use of dapagliflozin in T2DM were identified (Table 2) [18]-[28]. The majority of trials evaluated the effectiveness of dapagliflozin as add-on therapy to standard treatments [18] [20] [22] [24]-[28]. The time period for the 11 studies ranged from 12 to 102 weeks, and investigators used dapagliflozin

doses of 1 - 20 mg [18]-[28]. Dapagliflozin consistently showed statistically significant decreases in mean HbA1C (%) compared to control groups [18]-[23] [25] [26] [28]. The largest difference in HbA1C (%) reduction between dapagliflozin and placebo groups was -0.84% after 24 weeks of treatment with dapagliflozin 5 mg [19]. No difference in the adjusted mean change in HbA1C (%) from baseline between the dapagliflozin and glipizide groups was observed in a 52-week study, which concluded that dapagliflozin was statistically noninferior to glipizide [24]. A few trials found a statistically significant difference in patients achieving an HbA1C of <7% at the end of the study period in the dapagliflozin treatment groups compared to placebo [18]-[20] [22] [26].

The majority of studies found a statistically significant decrease with mean FPG in dapagliflozin treatment groups compared to control groups [18]-[23] [25] [26] [28]. Three of the four studies that assessed 2-h PPG after an oral glucose tolerance test (OGTT) found statistically significant decreases in dapagliflozin groups compared to control groups [19] [25] [26]. Although [27] did not report statistical significance, 2-h PPG was found to be lower in the dapagliflozin groups. All studies found a greater decrease in body weight after treatment with dapagliflozin compared to the control [18]-[28].

The most common adverse events were diarrhea, headache, nasopharyngitis, upper respiratory tract infection, urinary tract infection, influenza, back pain, hypertension, cough, and arthralgia [18]-[28]. Nine trials documented >55% of subjects experiencing at least one adverse event but <10% of subjects discontinued a study due to an adverse event [18]-[22] [24] [25] [27] [28]. Fewer adverse events overall were reported by [23] (38.9% - 53.8%) and [26] (47.3% - 51.9%). Of the reported events, approximately 25% or fewer were determined to be drug-related in five trials [18]-[20] [22] [26]. The overall incidence of urinary and genital tract infections was low (<15%), but more common in dapagliflozin groups compared to control groups [18]-[25] [27] [28]. In five of the studies, the events were reported as mild or moderate and responded adequately to treatment [18]-[21] [26]. Among four other trials, there was a total of 12 patients who withdrew from the study because of a UTI or genital infection [24]-[26] [28].

Hypoglycemic events did not occur frequently (<10%) or severely and were similar to placebo or treatment groups in most studies [18]-[23] [25]. The incidence of hypoglycemia was higher in treatment groups using dapagliflozin with hypoglycemia-associated medications such as insulin (25% - 29.2% versus 13% in placebo) [28], insulin with insulin-sensitizers (53.6% - 60.4% versus 51.8% in placebo) [27] and sulfonylureas (6.9% - 7.9% versus 4.8% in placebo) [26]. A serious adverse event related to hypoglycemia was also reported for dapagliflozin 5 mg [28]. A significantly higher proportion of patients experienced hypoglycemia on glipizide (40.8%) compared to dapagliflozin (3.5%) with six episodes of hypoglycemia leading to discontinuation in the glipizide group [24].

Blood pressure was also monitored in trials. Some studies reported that systolic blood pressure was slightly reduced in both dapagliflozin and control groups [18] [21] [22] [26] [28], while others reported that it was lowered only in dapagliflozin treatment groups compared to control groups [19] [20] [23]-[25] [27]. Overall, most studies found that dapagliflozin treatment was associated with only a few incidences of hypotension (<5%) [18]-[22] [24] [28]. An incidence of syncope was reported in a patient receiving dapagliflozin 10 mg [26], while an episode of severe hypotension was noted in a patient on dapagliflozin 5 mg [19].

### 3.3. Empagliflozin

Approved by the FDA in August 2014, empagliflozin, D-Glucitol,1,5-anhydro-1-C-[4-chloro-3-[[4-[[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-, (1S), is the newest SGLT2 inhibitor to enter the market. Similar to the other available agents, empagliflozin is approved for use in T2DM patients, as an adjunct to diet and exercise [3]. Plasma concentrations peak at approximately 1.5 hours post-oral administration [3] [29] with a reduction in AUC (16%) and  $C_{max}$  (37%) when taken after a high-fat and high-calorie meal. Although reductions in systemic exposure were noted, the impact on clinical outcomes was not deemed significant. As a result, empagliflozin may be taken with or without food. Empagliflozin has a plasma protein binding of roughly 86%. Metabolism occurs primarily via glucuronidation with minimal metabolite exposure. The terminal half-life of empagliflozin is 12.4 hours. Empagliflozin is primarily eliminated renally. Increases in AUC have occurred in patients with renal impairment, kidney failure or ESRD. Empagliflozin is contraindicated in severe renal impairment, ESRD, or dialysis [3].

The impact on plasma concentration varies based on the degree of renal and hepatic impairment. Patients with moderate renal impairment, kidney failure, or ESRD have peak plasma concentrations comparable to patients

**Table 2.** Dapagliflozin trials.

Author (Year)	Study Design	Subjects	Methods	Results			
Wilding (2009)	Randomized Double-blind Placebo-controlled	71 T2DM (42M; 29F)	Stabilization of Insulin Sensitizer Therapy and Insulin: ≥6 weeks with insulin treatment for ≥12 weeks	HbA1C (%) at 12 Weeks			
					Baseline Mean ± SD	Adjusted Mean Change (95% CI)	Difference vs. PBO (95% CI)
				PBO (N = 23)	8.4 ± 0.9	0.03 (-0.2, 0.4)	-
				DAPA 10 mg (N = 24)	8.4 ± 0.7	-0.61 (-0.9, -0.4)	-0.7 (-1.1, -0.3)
				DAPA 20 mg (N = 24)	8.5 ± 0.9	-0.69 (-0.9, -0.4)	-0.78 (-1.2, -0.4)
				FPG (mg/dL) at 12 Weeks			
					Baseline Mean ± SD	Adjusted Mean Change (95% CI)	Difference vs. PBO (95% CI)
				PBO (N = 23)	165.9 ± 51.5	17.8 (1.4, 34.2)	-
				DAPA 10 mg (N = 24)	156.0 ± 39.0	2.4 (-13.6, 18.3)	-15.4 (-38.4, 7.5)
				DAPA 20 mg (N = 24)	161.6 ± 55.0	-9.6 (-25.6, 6.3)	-27.4 (-50.3, -4.6)
				Body Weight (kg) at 12 Weeks			
					Baseline Mean ± SD	Adjusted Mean Change (95% CI)	Difference vs. PBO (95% CI)
PBO (N = 23)	101.8 ± 16.5	-1.9 (-2.9, -0.9)	-				
DAPA 10 mg (N = 24)	103.4 ± 10.2	-4.5 (-5.5, -3.5)	-2.6 (-4.0, -1.2)				
DAPA 20 mg (N = 24)	101.2 ± 15.3	-4.3 (-5.3, -3.3)	-2.4 (-3.8, -1.0)				
Bailey (2010)	Randomized Double-blind Parallel Group Placebo-Controlled	546 T2DM (292M; 254F)	Single-blind, Placebo Lead-in Period : 2 weeks	HbA1C (%) at 24 Weeks			
				Baseline Mean ± SD	Adjusted Mean Change (95% CI)	Difference vs. PBO (95% CI)	
			Double-blind Treatment Period: 24 weeks (All groups on stable MET dose)	PBO (N = 137)	8.11 ± 0.96	-0.3 (-0.44, -0.16)	-
			Group A: placebo + MET daily in AM	DAPA 2.5 mg (N = 137)	7.99 ± 0.90	-0.67 <sup>*†</sup> (-0.81, -0.53)	-
			Group B: DAPA 2.5 mg + MET daily in AM	DAPA 5 mg (N = 137)	8.17 ± 0.96	-0.70 <sup>*†</sup> (-0.85, -0.56)	-
			Group C: DAPA 5 mg + MET daily in AM	DAPA 10 mg (N = 135)	7.92 ± 0.82	-0.84 <sup>**†</sup> (-0.98, -0.70)	-
			* p = 0.0002				
			** p < 0.0001				

Continued

				†Significant vs. PBO at $\alpha = 0.019$ applying Dunnett's adjustment			
				FPG (mg/dL) at 24 Weeks			
				Baseline Mean $\pm$ SD	Adjusted Mean Change (95% CI)	Difference vs. PBO (95% CI)	
Group D: DAPA 10 mg + MET daily in AM				PBO (N = 137)	165.6 $\pm$ 46.3	-5.9 (-11.2, -0.7)	-
				DAPA 2.5 mg (N = 137)	161.4 $\pm$ 43.1	-17.8 <sup>††</sup> (-23.1, -12.4)	-
				DAPA 5 mg (N = 137)	169.2 $\pm$ 49.0	-21.4 <sup>**†</sup> (-26.8, -16.2)	-
				DAPA 10 mg (N = 135)	156.0 $\pm$ 38.7	-23.4 <sup>**†</sup> (-28.8, -18.0)	-
* p = 0.0019							
** p < 0.0001							
Double-blind Extension Period: to 102 weeks (refer to Bailey 2013)				†Significant after sequential testing procedure at $\alpha=0.05$			
				Body Weight (kg) at 24 Weeks			
				Baseline Mean $\pm$ SD	Adjusted Mean Change (95% CI)	Difference vs. PBO	
				PBO (N = 137)	87.7 $\pm$ 19.2	-0.9 (-1.4, -0.4)	-
				DAPA 2.5 mg (N = 137)	84.9 $\pm$ 17.8	-2.2 <sup>†</sup> (-2.7, -1.8)	-
				DAPA 5 mg (N = 137)	84.7 $\pm$ 16.3	-3.0 <sup>†</sup> (-3.5, -2.6)	-
				DAPA 10 mg (N = 135)	86.3 $\pm$ 17.5	-2.9 <sup>†</sup> (-3.3, -2.4)	-
* p < 0.0001							
				†Significant after sequential testing procedure at $\alpha=0.05$			
				HbA1C (%) at 24 Weeks			
				Baseline Mean $\pm$ SD	Adjusted Mean Change (95% CI)	Difference vs. PBO	
Ferrannini (2010) Randomized Double-blind Parallel-group Placebo-controlled Total: 558 T2DM (276M; 282F) Main AM Cohort: 274 T2DM (132M; 142F) Diet/exercise Placebo Lead-in Period: 2 weeks (1 week for patients with enrollment HbA1C 10.1% - 12%) Double-blind Placebo Controlled Treatment Period: 24 weeks Patients with HbA1C 7.0% - 10% entered main AM cohort groups: Group A: placebo daily in AM				PBO (N = 75)	7.84 $\pm$ 0.87	-0.23 (-0.43, -0.02)	-
				DAPA 2.5 mg (N = 65)	7.92 $\pm$ 0.90	-0.58 (-0.80, -0.36)	-
				DAPA 5 mg (N = 64)	7.86 $\pm$ 0.94	-0.77 <sup>*</sup> (-0.99, -0.55)	-
				DAPA 10 mg (N = 70)	8.01 $\pm$ 0.96	-0.89 <sup>**</sup> (-1.10, -0.67)	-
* p = 0.0005 vs. PBO							
** p < 0.0001 vs. PBO							
				FPG (mg/dL) at 24 Weeks			

Continued

			Baseline Mean ± SD	Adjusted Mean Change (95% CI)	Difference vs. PBO	
			PBO (N = 75)	159.9 ± 42.1	-4.1 (-11.8, 3.5)	-
			DAPA 2.5 mg (N = 65)	164.1 ± 48.0	-15.2 (-23.5, -7.0)	-
			DAPA 5 mg (N = 64)	162.2 ± 45.0	-24.1* (-32.5, -15.6)	-
			DAPA 10 mg (N = 70)	166.6 ± 41.5	-28.8** (-36.8, -20.9)	-
Group B: DAPA 2.5 mg daily in AM						
Group C: DAPA 5 mg daily in AM			* p < 0.001			
Group D: DAPA 10 mg daily in AM			** p < 0.0001 (α = 0.019 [two-sided] applyinh Dunnnett adjustment)			
(Exploratory cohort assessments not included)			Body Weight (kg) at 24 Weeks			
			Baseline Mean ± SD	Adjusted Mean Change (95% CI)	Difference vs. PBO	
			PBO (N = 75)	88.8 ± 19.0	-2.2 (-3.3, -1.3)	-
			DAPA 2.5 mg (N = 65)	90.8 ± 22.8	-3.3 (-4.2, -2.3)	-
			DAPA 5 mg (N = 64)	87.6 ± 17.1	-2.8 (-3.8, -1.9)	-
			DAPA 10 mg (N = 70)	94.2 ± 18.7	-3.2 (-4.0, -2.3)	-
			HbA1C (%) at 52 Weeks			
MET Stabilization Period: 8 weeks			Baseline Mean ± SD	Adjusted Mean Change (95% CI)	Difference vs. GLIP (95% CI)	
Single-blind, Placebo Lead-in Period: 2 weeks			GLIP (N = 401)	7.7 ± 0.9	-0.52 (-0.60, 0.44)	-
Double-blind Treatment Period: 52 weeks (18-week titration period with 3 week intervals and 34-week maintenance period)			DAPA (N = 400)	7.7 ± 0.9	-0.52 (-0.60, 0.44)	0 (-0.11, 0.11)
			FPG (mg/dL) at 52 Weeks			
			Baseline Mean	Adjusted Mean Change (95% CI)	Difference vs. GLIP (95% CI)	
			GLIP (N = 401)	164.0 ± 41.4	-18.7 (-22.0, -17.7)	-
			DAPA (N = 400)	162.2 ± 37.8	-22.3 (-25.6, -19.3)	-3.6 (-7.9, 0.9)
			Body Weight (kg) at 52 Weeks			
			Baseline Mean	Adjusted Mean Change (95% CI)	Difference vs. GLIP (95% CI)	
Group B GLIP 5 mg, titrated to 10 or 20 mg if FPG ≥ 6.1 mmol/L + metformin			GLIP (N = 401)	87.6	1.44 (1.09, 1.78)	-
Extension Period: 156 weeks			DAPA (N = 400)	88.4	-3.22 (-3.56, -2.87)	-4.65* (-5.14, -4.17)
			* p < 0.0001 vs. GLIP			



Continued

			HbA1C (%) at 24 Weeks					
			Baseline Mean $\pm$ SD	Adjusted Mean Change	Difference vs. PBO (95% CI)			
Strojek (2011)	Randomized Double-blind Parallel-group Placebo-Controlled	592 T2DM (285M; 307F)	Open-label, Lead in Period: 8 weeks of GLIM daily	PBO (N = 145)	8.15 $\pm$ 0.74	-0.13	-	
				DAPA 2.5 mg (N = 154)	8.11 $\pm$ 0.75	-0.58	-0.44* (-0.61, -0.27)	
				DAPA 5 mg (N = 142)	8.12 $\pm$ 0.78	-0.63	-0.49* (-0.67, -0.32)	
				DAPA 10 mg (N = 151)	8.07 $\pm$ 0.79	-0.82	-0.68* (-0.86, -0.51)	
			Qualification Period: 1 week	* p < 0.0001 vs. PBO at $\alpha$ = 0.019 applying Dunnett's adjustment				
				FPG (mg/dL) at 24 Weeks				
			Double-blind Placebo-controlled Treatment Period: 24 weeks		Baseline Mean $\pm$ SD	Adjusted Mean Change	Difference vs. PBO (95% CI)	
				PBO (N = 145)	172.6 $\pm$ 37.3	-2	-	
			Group A: placebo before first meal of day + GLIM	DAPA 2.5 mg (N = 154)	172.3 $\pm$ 38.4	-16.8	-15 (-21.8, -7.9)	
			Group B: DAPA 2.5 mg daily before first meal of day + GLIM	DAPA 5 mg (N = 142)	174.4 $\pm$ 38.2	-21.3	-19.3* (-26.3, -12.3)	
			Group C: DAPA 5 mg daily before first meal of day + GLIM	DAPA 10 mg (N = 151)	172.1 $\pm$ 36.8	-28.5	-26.5* (-33.5, -19.5)	
				* p < 0.0001 vs. PBO				
	Body Weight (kg) at 24 Weeks							
		Baseline Mean	Adjusted Mean Change	Difference vs. PBO (95% CI)				
Group D: DAPA 10 mg daily before first meal of day + GLIM	PBO (N = 145)	80.94	-0.72	-				
Extension Period: 24 weeks	DAPA 2.5 mg (N = 154)	81.89	-1.18	-0.46* (-1.08, 0.15)				
	DAPA 5 mg (N = 142)	81	-1.56	-0.84** (-1.47, -0.21)				
	DAPA 10 mg (N = 151)	80.56	-2.26	-1.54*** (-2.17, -0.92)				
		* p = 0.1410 vs. PBO ** p = 0.0091 vs. PBO (significant after sequential testing procedure at $\alpha$ = 0.05) *** p < 0.0001 vs. PBO (significant after sequential testing procedure at $\alpha$ = 0.05)						
Bailey (2012)	Randomized Double-blind Parallel-group Placebo-controlled	282 T2DM (141M; 141F)	Qualification Period: 2 weeks	HbA1C (%) at 24 Weeks				
			Single-blind, Placebo Lead-in Period: 2 weeks		Baseline Mean $\pm$ SD	Adjusted Mean Change (95% CI)	Difference vs. PBO (95% CI)	
				PBO (N = 68)	7.8 $\pm$ 1.12	0.02 (-0.22, 0.25)	-	
	DAPA 1 mg (N = 72)	7.8 $\pm$ 0.98	-0.68	-0.69*				

Continued

						(-0.91, -0.45)	(-1.02, -0.37)
				DAPA 2.5 mg (N = 74)	8.1 ± 1.07	-0.72 (-0.95, -0.49)	-0.74* (-1.07, -0.41)
				DAPA 5 mg (N = 68)	7.9 ± 1.03	-0.82 (-1.06, -0.58)	-0.84* (-1.17, -0.50)
				* p < 0.0001 vs. PBO			
				FPG (mg/dL) at 24 Weeks			
					Baseline Mean ± SD	Adjusted Mean Change (95% CI)	Difference vs. PBO (95% CI)
			Double-blind Treatment Period: 24 weeks	PBO (N = 68)	161.6 ± 57.5	4.1 (-4.1, 12.4)	-
			Group A: placebo daily with morning meal	DAPA 1 mg (N = 72)	155.5 ± 48.3	-11 (-19.1, -3.1)	-15.1* (-26.7, -3.6)
			Group B: DAPA 1 mg daily with morning meal	DAPA 2.5 mg (N = 74)	159.8 ± 51.5	-21.6 (-29.5, -13.7)	-25.8** (-37.1, -14.2)
				DAPA 5 mg (N = 68)	157.1 ± 41.6	-28.5 (-36.8, -20.2)	-32.6** (-44.3, -20.7)
			Group C: DAPA 2.5 mg daily with morning meal	* p = 0.0103 vs. PBO			
				** p < 0.0001 vs. PBO			
			Group D: DAPA 5 mg daily with morning meal	Body Weight (kg) at 24 Weeks			
					Baseline Mean ± SD	Adjusted Mean Change (95% CI)	Difference vs. PBO (95% CI)
			Safety-assessment Follow-up Period: 4 weeks	PBO (N = 68)	90.0 ± 17.98	-0.96 (-1.74, -0.19)	-
				DAPA 1 mg (N = 72)	88.2 ± 18.49	-2.69 (-3.44, -1.94)	-1.73* (-2.81, -0.65)
				DAPA 2.5 mg (N = 74)	84.3 ± 18.18	-2.64 (-3.38, -1.90)	-1.68** (-2.76, -0.60)
				DAPA 5 mg (N = 68)	85.4 ± 19.43	-2.69 (-3.47, -1.91)	-1.73*** (-2.83, -0.63)
				* p = 0.0018 vs. PBO			
				** p = 0.0024 vs. PBO			
				*** p = 0.0022 vs. PBO			
			Single-blind Placebo Lead-in Period: 1 week	HbA1C (%) at 24 Weeks - Study I			
					Baseline Mean ± SD	Adjusted Mean Change (95% CI)	Difference vs. Monotherapy (95% CI)
Henry (2012)	Two Randomized Double-blind Active-controlled	1236 T2DM (573M; 663F)	Double-blind Treatment Period: 24 weeks	MET + PBO (N = 201)	9.2 ± 1.3	-1.35 (-1.53, -1.18)	-
			Study I: Group A: MET XR + placebo combination with evening meal	DAPA 5 mg + MET (N = 194)	9.2 ± 1.3	-2.05 (-2.23, -1.88)	-0.86* (-1.11, -0.62) -0.70** (-0.94, -0.45)

Continued

	DAPA 5 mg + PBO (N = 203)	9.1 ± 1.4	-1.19 (-1.36, -1.02)	-
	HbA1C (%) at 24 Weeks - Study II			
		Baseline Mean ± SD	Adjusted Mean Change (95% CI)	Difference vs. Monotherapy (95% CI)
	MET + PBO (N = 208)	9.1 ± 1.3	-1.44 (-1.59, -1.29)	-
	DAPA 10 mg + MET (N = 211)	9.1 ± 1.3	-1.98 (-2.13, -1.83)	-0.53* (-0.74, -0.32) -0.54** (-0.75, -0.33)
	DAPA 10 mg + PBO (N = 219)	9.1 ± 1.3	-1.45 (-1.59, -1.31)	-
Group B: DAPA 5 mg + MET XR combination with evening meal			*p < 0.0001 vs. DAPA + PBO **p < 0.0001 vs. MET + PBO	
	FPG (mg/dL) at 24 Weeks - Study I			
Group C: DAPA 5 mg + placebo combination with evening meal		Baseline Mean ± SD	Adjusted Mean Change (95% CI)	Difference vs. Monotherapy (95% CI)
	MET + PBO (N = 201)	197.1 ± 60.4	-33.5 (-38.9, -28.3)	-
Study II: Group A: MET XR + placebo combination with evening meal	DAPA 5 mg + MET (N = 194)	193.9 ± 56.2	-61.1 (-66.5, -55.7)	-19.1* (-26.7, -11.4) -27.6** (-35.1, -19.8)
Group B: DAPA 10 mg + MET XR combination with evening meal	DAPA 5 mg + PBO (N = 203)	190.8 ± 56.6	-42 (-47.4, -36.8)	-
	FPG (mg/dL) at 24 Weeks - Study II			
Group C: DAPA 10 mg + placebo combination with evening meal		Baseline Mean ± SD	Adjusted Mean Change (95% CI)	Difference vs. Monotherapy (95% CI)
	MET + PBO (N = 208)	190.5 ± 54.1	-34.8 (-39.8, -29.7)	-
	DAPA 10 mg + MET (N = 211)	189.5 ± 58.0	-60.4 (-65.2, -55.3)	-13.9* (-20.9, -7.0) -25.6** (-32.6, -18.6)
	DAPA 10 mg + PBO (N = 219)	198.0 ± 61.8	-46.5 (-51.4, -41.4)	-
			*p < 0.0001 vs. DAPA + PBO (after sequential testing procedure at $\alpha = 0.05$ ) **p < 0.0001 vs. MET + PBO (after sequential testing procedure at $\alpha = 0.05$ )	
	Body Weight (kg) at 24 Weeks - Study I			
		Baseline Mean ± SD	Adjusted Mean Change (95% CI)	Difference vs. Monotherapy (95% CI)

Continued

			MET + PBO (N = 201)	85.6 ± 20.0	-1.29 (-1.76 to -0.82)	-
			DAPA 5 mg + MET (N = 194)	84.1 ± 19.5	-2.66 (-3.14, -2.19)	-0.05* (-0.72, 0.61)
			DAPA 5 mg + PBO (N = 203)	86.2 ± 21.1	-2.61 (-3.07, -2.15)	-1.37** (-2.04, -0.71)
Body Weight (kg) at 24 Weeks - Study II						
			Baseline Mean ± SD	Adjusted Mean Change (95% CI)	Difference vs. Monotherapy (95% CI)	
			MET + PBO (N = 208)	87.2 ± 19.4	-1.36 (-1.83, -0.89)	-
			DAPA 10 mg + MET (N = 211)	88.4 ± 19.7	-3.33 (-3.80, -2.86)	-1.97*** (-2.64, -1.30)
			DAPA 10 mg + PBO (N = 219)	88.5 ± 19.3	-2.73 (-3.19, -2.27)	-1.37**** (-2.03, -0.71)
			* p = 0.8769 vs. DAPA + PBO			
			** p < 0.0001 vs. MET + PBO			
			*** p < 0.0001 vs. MET + PBO (after sequential testing procedure at α = 0.05)			
			**** p < 0.0001 vs. DAPA vs. MET (after sequential testing procedure at α = 0.05)			
			HbA1C (%) at 24 Weeks			
			Baseline Mean ± SD	Adjusted Mean Change ± SE	Difference vs. PBO	
			PBO (N = 139)	8.34 ± 1.00	-0.42 ± 0.08	-
			DAPA 5 mg (N = 141)	8.40 ± 1.03	-0.82 ± 0.08*	-
			DAPA 10 mg (N = 140)	8.37 ± 0.96	-0.97 ± 0.08**	-
			* p = 0.0007 vs. PBO			
			** p < 0.0001 vs. PBO			
			FPG (mg/dL) at 24 Weeks			
			Baseline Mean ± SD	Adjusted Mean Change ± SE	Difference vs. PBO	
			PBO (N = 139)	160.7 ± 47.0	-5.5 ± 2.9	-
			DAPA 5 mg (N = 141)	168.6 ± 52.1	-24.9 ± 2.9*	-
			DAPA 10 mg (N = 140)	164.9 ± 46.3	-29.6 ± 2.9*	-
			* p < 0.0001 vs. PBO			
			Body Weight (kg) at 24 Weeks			
Rosenstock (2012)	Randomized Double-blind Parallel-group Placebo- Controlled	420 T2DM (208M; 212F)	PIO dose-optimization period for treatment-naïve patients or those receiving MET, SU, or low dose TZD: 10 weeks			
			Single-blind, Lead-in Period: 2 weeks			
			Double-blind Treatment Period: 24 weeks			
			Group A: placebo + PIO 30 mg or 45 mg			
			Group B: DAPA 5 mg + PIO 30 mg or 45 mg			
			Group C: DAPA 10 mg + PIO 30 mg or 45 mg			
			Extension Period: 24 weeks			

Continued

				Baseline Mean ± SD	Adjusted Mean Change ± SE	Difference vs. PBO	
				PBO (N = 139)	86.4 ± 21.3	1.64 ± 0.28	-
				DAPA 5 mg (N = 141)	87.8 ± 20.7	0.09 ± 0.28*	-
				DAPA 10 mg (N = 140)	84.8 ± 22.2	-0.14 ± 0.28*	-
				*p < 0.0001 vs. PBO			
				HbA1C (%) at 48 Weeks			
				Baseline Mean ± SD	Adjusted Mean Change (95% CI)	Difference vs. PBO	
				PBO (N = 139)	8.34 ± 1.00	-0.54 (-0.70, -0.38)	-
				DAPA 5 mg (N = 141)	8.40 ± 1.03	-0.95 (-1.10, -0.80)	-
				DAPA 10 mg (N = 140)	8.37 ± 0.96	-1.21 (-1.36, -1.06)	-
				FPG (mg/dL) at 48 Weeks			
				Baseline Mean ± SD	Adjusted Mean Change (95% CI)	Difference vs. PBO	
				PBO (N = 139)	160.7 ± 47.0	-13.1 (-20.2, -6.0)	-
				DAPA 5 mg (N = 141)	168.6 ± 52.1	-22.8 (-29.1 to -16.4)	-
				DAPA 10 mg (N = 140)	164.9 ± 46.3	-33.1 (-39.0, -27.2)	-
				Body Weight (kg) at 48 Weeks			
				Baseline Mean ± SD	Adjusted Mean Change (95% CI)	Difference vs. PBO	
				PBO (N = 139)	86.4 ± 21.3	2.99 (2.19, 3.79)	-
				DAPA 5 mg (N = 141)	87.8 ± 20.7	1.35 (0.61, 2.09)	-
				DAPA 10 mg (N = 140)	84.8 ± 22.2	0.69 (-0.03, 1.41)	-
				HbA1C (%) at 24 Weeks			
				Baseline Mean ± SD	Adjusted Mean Change	Difference vs. PBO (95% CI)	
Wilding (2012)	Randomized Double-blind Parallel-group Placebo- controlled	800 T2DM (382M; 418F)	Pre-enrollment OAD/ Insulin Stabilization Period: at least 8 weeks	PBO (N = 193)	8.47 ± 0.77	-0.39	-
			Enrollment Period: 2 weeks	DAPA 2.5 mg (N = 202)	8.46 ± 0.78	-0.79	-0.40* (-0.54, -0.25)

**Continued**

	DAPA 5 mg (N = 211)	8.62 ± 0.89	-0.89	-0.49* (-0.65, -0.34)
	DAPA 10 mg (N = 194)	8.57 ± 0.82	-0.96	-0.57* (-0.72, -0.42)
	*p < 0.001 vs. PBO			
	FPG (mg/dL) at 24 Weeks			
		Baseline Mean ± SD	Adjusted Mean Change (95% CI)	Difference vs. PBO
	PBO (N = 193)	170.6 ± 57.2	-	-
	DAPA 2.5 mg (N = 202)	180.1 ± 59.9	-11.71* (-21.4, -2.0)	-
Double-blind Placebo-controlled Treatment Period: 24 weeks (with open-label insulin/existing OAD therapies)	DAPA 5 mg (N = 211)	185.4 ± 58.7	-20.18* (-29.9, -10.6)	-
	DAPA 10 mg (N = 194)	173.1 ± 54.9	-19.82* (-29.6, -10.1)	-
	*p < 0.001 vs. baseline			
Group A: placebo + insulin	Body Weight (kg) at 24 Weeks			
Group B: DAPA 2.5 mg daily + insulin		Baseline Mean ± SD	Adjusted Mean Change	Difference vs. PBO (95% CI)
	PBO (N = 193)	94.5 ± 19.8	0.43	-
Group C: DAPA 5 mg daily + insulin	DAPA 2.5 mg (N = 202)	93.0 ± 16.7	-0.92	-1.35* (-1.90, -0.80)
Group D: DAPA 10 mg daily + insulin	DAPA 5 mg (N = 211)	93.3 ± 17.4	-1	-1.42* (-1.97, -0.88)
Double-blind Extension Period I: 24 weeks	DAPA 10 mg (N = 194)	94.5 ± 16.8	-1.61	-2.04* (-2.59, -1.48)
Double-blind Extension Period II: 56 weeks	*p < 0.001 vs. PBO			
	HbA1C (%) at 48 Weeks			
		Baseline Mean ± SD	Adjusted Mean Change	Difference vs. PBO (95% CI)
	PBO (N = 193)	8.47 ± 0.77	-0.47	-
	DAPA 2.5 mg (N = 202)	8.46 ± 0.78	-0.79	-0.32* (-0.48, -0.16)
	DAPA 5 mg (N = 211)	8.62 ± 0.89	-0.96	-0.49* (-0.65, -0.33)
	DAPA 10 mg (N = 194)	8.57 ± 0.82	-1.01	-0.54* (-0.70, -0.38)
	*p < 0.001 vs. PBO			
	FPG (mg/dL) at 48 Weeks			

Continued

			Baseline Mean ± SD	Adjusted Mean Change (95% CI)	Difference vs. PBO			
			PBO (N = 193)	170.6 ± 57.2	-			
			DAPA 2.5 mg (N = 202)	180.1 ± 59.9	-12.43* (-23.1, -2.0)			
			DAPA 5 mg (N = 211)	185.4 ± 58.7	-16.2* (-26.7, -6.0)			
			DAPA 10 mg (N = 194)	173.1 ± 54.9	-16.94* (-27.6, -6.5)			
*p < 0.001 vs. baseline								
			Body Weight (kg) at 48 Weeks					
			Baseline Mean ± SD	Adjusted Mean Change	Difference vs. PBO (95% CI)			
			PBO (N = 193)	94.5 ± 19.8	0.82			
			DAPA 2.5 mg (N = 202)	93.0 ± 16.7	-0.96 (-2.53, -1.03)			
			DAPA 5 mg (N = 211)	93.3 ± 17.4	-1 (-2.56, -1.07)			
			DAPA 10 mg (N = 194)	94.5 ± 16.8	-1.61 (-3.18, -1.68)			
*p < 0.001 vs. PBO								
			HbA1C (%) at 102 Weeks					
			Baseline Mean ± SD	Adjusted Mean Change (95% CI)	Difference vs. PBO (95% CI)			
Bailey (2013)	Randomized Double-blind Parallel Group Placebo- Controlled	546 T2DM (292M; 254F)	Double-blind Extension Treatment Period: 78 weeks (All groups on stable MET dose)	PBO (N = 137)	8.12 ± 0.96	0.02 (-0.20, 0.23)	-	
			Group A: placebo + MET daily in AM	DAPA 2.5 mg (N = 137)	7.99 ± 0.90	-0.48 (-0.68, -0.29)	-0.50* (-0.79, -0.21)	
				DAPA 5 mg (N = 137)	8.17 ± 0.96	-0.58 (-0.77, -0.39)	-0.60** (-0.89, -0.31)	
				DAPA 10 mg (N = 135)	7.92 ± 0.82	-0.78 (-0.97, -0.60)	-0.80** (-1.08, -0.52)	
				Group C: DAPA 5 mg + MET daily in AM	*p = 0.0008 **p < 0.0001 vs. PBO			
			Group D: DAPA 10 mg + MET daily in AM	FPG (mg/dL) at 102 Weeks				
				PBO (N = 137)	165.6 ± 46.5	-10.5 (-17.5, -3.4)	-	
					DAPA 2.5 mg	161.4 ± 43.1	-19.3	-8.8*

Continued

			(N = 137)		(-25.6, -13.0)	(-17.8, 0.2)
		DAPA 5 mg	169.2 ± 49.0		-26.5	-16.0**
			(N = 137)		(-32.1, -20.9)	(-24.7, -7.4)
		DAPA 10 mg	156.0 ± 38.7		-24.5	-14.1***
			(N = 135)		(-29.7, -19.3)	(-22.5, -5.6)
				*p = 0.0518 vs. PBO		
				**p = 0.0003 vs. PBO		
				***p = 0.0012 vs. PBO		
				Body Weight (kg) at 102 Weeks		
				Baseline Mean ± SD	Adjusted Mean Change (95% CI)	Difference vs. PBO (95% CI)
		PBO	87.74 ± 19.24		1.36	-
			(N = 137)		(0.53, 2.20)	
		DAPA 2.5 mg	84.90 ± 17.77		-1.1	-2.46*
			(N = 137)		(-1.91, -0.29)	(-3.63, -1.30)
		DAPA 5 mg	84.73 ± 16.26		-1.7	-3.06*
			(N = 137)		(-2.48, -0.91)	(-4.21, -1.92)
		DAPA 10 mg	86.28 ± 17.53		-1.74	-3.10*
			(N = 135)		(-2.51, -0.96)	(-4.24, -1.96)
				*p < 0.0001 vs. PBO		
				HbA1C (%) at 12 Weeks		
				Baseline Mean ± SD	Adjusted Mean Change ± SE	Difference vs. PBO (95% CI)
		Washout Period: 6 weeks if on prior OAD				
			PBO	8.12 ± 0.71	0.37 ± 0.07	-
			(N = 54)			
		Single-blind Placebo Lead-in Period: 4 weeks				
			DAPA 1 mg	8.10 ± 0.79	-0.12 ± 0.07	-0.49*
			(N = 59)			(-0.68, -0.29)
		Double-blind Treatment Period: 12 weeks				
			DAPA 2.5 mg	7.92 ± 0.74	-0.11 ± 0.07	-0.48*
			(N = 56)			(-0.67, -0.28)
		Group A: placebo daily				
			DAPA 5 mg	8.05 ± 0.66	-0.37 ± 0.07	-0.74*
			(N = 58)			(-0.93, -0.54)
		Group B: DAPA 1 mg daily				
			DAPA 10 mg	8.18 ± 0.69	-0.44 ± 0.07	-0.80*
			(N = 52)			(-1.00, -0.61)
		Group C: DAPA 2.5 mg daily				
				*p < 0.0001 vs. PBO (tested at α = 0.015 applying Dunnett adjustment)		
		Group D: DAPA 5 mg daily		FPG (mg/dL) at 12 Weeks		
				Baseline Mean ± SD	Adjusted Mean Change ± SE	Difference vs. PBO
		Group E: DAPA 10 mg daily				
			PBO	158.94 ± 31.08	11.17 ± 3.43	-
			(N = 54)			
		Follow-up Period: 4 weeks				
			DAPA 1 mg	163.53 ± 33.06	-15.61 ± 3.43*	-
			(N = 59)			
			DAPA 2.5 mg	159.17 ± 31.98	-19.83 ± 3.37*	-
			(N = 56)			



Continued

DAPA 5 mg (N = 58)	164.49 ± 23.56	-23.51 ± 3.43*	-
DAPA 10 mg (N = 52)	163.36 ± 29.74	-31.94 ± 3.57*	-
*p < 0.0001 vs. PBO			
Body Weight (kg) at 12 Weeks			
	Baseline Mean ± SD	Adjusted Mean Change ± SE	Difference vs. PBO
PBO (n = 54)	68.88 ± 14.94	-0.05 ± 0.19	-
DAPA 1 mg (n = 59)	68.40 ± 11.04	-1.25 ± 0.18*	-
DAPA 2.5 mg (n = 56)	66.61 ± 14.29	-1.24 ± 0.18*	-
DAPA 5 mg (n = 58)	68.92 ± 12.43	-2.06 ± 0.18*	-
DAPA 10 mg (n = 52)	70.35 ± 17.48	-1.91 ± 0.19*	-
*p < 0.0001 vs. PBO			

95% CI = 95% confidence interval; AHA = antihyperglycemic agent; AM = morning; DAPA = dapagliflozin; F = Female; FPG = Fasting Plasma Glucose; GLIM = glimepiride; GLIP = glipizide; HbA1C = hemoglobin A1C; M = Male; MET = metformin; PBO = placebo; SD = standard deviation; SE = standard error; SITA = sitagliptin; SU = sulfonylurea; T2DM = Type 2 Diabetes Mellitus Patients; TZD = thiazolidinedione.

with normal renal function. On the other hand, patients with mild and severe renal impairment have approximately 20% higher peak plasma concentrations. Renal function should be evaluated prior to and throughout empagliflozin treatment. Use of empagliflozin should be avoided in patients with eGFR's of <45 mL/min/1.73m<sup>2</sup>. Mild to severe hepatic impairment may also result in AUC and C<sub>max</sub> elevations, but dose adjustments are not warranted [3].

Two pivotal trials evaluating the efficacy of empagliflozin in T2DM patients over 12 weeks\* were identified and summarized in **Table 3**. One study [30] assessed empagliflozin as monotherapy and another [31] as add-on therapy to metformin. Doses ranged from 1 mg to 50 mg. Significant reductions in HbA1C, FPG, and weight were observed in the 5 mg, 10 mg, 25 mg, and 50 mg empagliflozin groups when compared to placebo [30] [31]. Both studies reported greater proportions of empagliflozin groups reaching HbA1Cs ≤ 7% compared to placebo (30% - 45% of empagliflozin 5 mg and 25 mg versus 22% of placebo [30] and 35.7% - 38.0% of empagliflozin 10 mg, 25 mg, and 50 mg versus 15.5% of placebo [31]). Similar reductions were observed with sitagliptin 100 mg (33.8%) compared to placebo (15.5%) [31].

Overall, adverse events were similar among empagliflozin, placebo, and open-label agent groups. Pollakiuria, thirst, nasopharyngitis, urinary tract infections, and genital infections were the most common adverse events reported by empagliflozin subjects. Although the incidence of UTIs was comparable among study groups within each trial, an increased number of genital infections occurred in the empagliflozin groups. Hypoglycemic episodes among treatment and placebo groups were not significantly different. Additionally, both studies reported a trend toward a potential dose-related increase in hematocrit in the empagliflozin groups (0.6% - 2.5%) [30] [31]. Blood pressure (systolic and diastolic) changes trended toward dose-dependent decreases in the empagliflozin (5 mg, 10 mg, and 25 mg) versus placebo groups but were not statistically significant. The greatest change occurred in the empagliflozin 25 mg group [31].

### 3.4. Other SGLT2s

Although canagliflozin, dapagliflozin, and empagliflozin are the only SGLT2 inhibitors on the US market, several other candidates are currently in development. These include ipragliflozin, tofogliflozin, and ertugliflozin.

**Table 3.** Empagliflozin trials.

Author (Year)	Study Design	Subjects	Methods	Results							
Ferrannini (2013)	Randomized Double-blind Placebo-controlled	406 T2DM (211M; 195F)	Screening Period: up to 1 week (2 visits) Oral AHA Washout Period (if applicable): 4 weeks Open-label Placebo Run-in Period: 2 weeks	HbA1C (%) at 12 Weeks							
				Baseline Mean ± SD	Adjusted Mean Change (95% CI)	Difference vs. PBO (95% CI)					
				PBO (N = 82)	7.8 ± 0.8	0.1 (-0.09, 0.27)	-				
				EMPA 5 mg (N = 81)	7.9 ± 0.8	0.4* (-0.61, -0.25)	-				
				EMPA 10 mg -81	8.0 ± 0.8	-0.5* (-0.66, -0.30)	-				
				EMPA 25 mg (N = 82)	7.8 ± 0.8	-0.6* (-0.81, -0.45)	-				
				MET (N = 80)	8.1 ± 0.9	-0.7* (-0.92, -0.57)	-				
				* p < 0.0001 vs. PBO							
				Double-blind Treatment Period: 12 weeks			FPG (mg/dL) at 12 Weeks				
				Baseline Mean ± SD			Adjusted Mean Change (95% CI)			Difference vs. PBO (95% CI)	
			Group A: placebo once daily			PBO (N = 82)	171.2 ± 39.6	0.7 (-6.3, 7.7)	-		
			Group B: EMPA 5 mg once daily			EMPA 5 mg (N = 81)	178.4 ± 45.0	-23.2* (-30.5, -16.2)	-		
			Group C: EMPA10 mg once daily			EMPA 10 mg -81	178.4 ± 46.8	-29.0* (-36.0, -21.8)	-		
			Group D: EMPA 25 mg once daily			EMPA 25 mg (N = 82)	171.2 ± 25.2	-31.0* (-38.2, -24.1)	-		
			Group E: Open-label MET (up to 1000 mg twice daily or maximum tolerated dose)			MET (N = 80)	176.6 ± 43.2	-29.9* (-38.0, -21.8)	-		
			Follow-up Visit: 4 - 7 days after last treatment			Body Weight (kg) at 12 Weeks					
			Baseline Mean			Adjusted Mean Change (95% CI)			Difference vs. PBO (95% CI)		
			PBO (N = 82)			82.2	-0.75 (-1.26, -0.23)	-			
			EMPA 5 mg (N = 81)			82.8	-1.81 (-2.32, -1.29)	-			
			EMPA 10 mg -81			76.8	-2.33 (-2.84, -1.82)	-			
EMPA 25 mg (N = 82)			81.2	-2.03 (-2.54, -1.52)	-						
MET (N = 80)			81.1	-1.32 (-1.84, -0.81)	-						

Continued

			HbA1C (%) at 12 Weeks				
			Baseline Mean ± SD	Adjusted Mean Change (95% CI)	Difference vs. PBO (95% CI)		
			PBO (N = 71)	8.0 ± 0.7	0.15 (-0.00, 0.30)	-	
			EMPA 1 mg (N = 71)	7.8 ± 0.7	-0.09 (-0.24, 0.07)	-	
			EMPA 5 mg -71	8.0 ± 0.7	-0.23* (-0.39, -0.08)	-	
			EMPA 10 mg (N = 71)	7.9 ± 0.7	-0.56** (-0.71, -0.41)	-	
			EMPA 25 mg (N = 70)	8.1 ± 0.8	-0.55** (-0.70, -0.40)	-	
			EMPA 50 mg (N = 70)	7.9 ± 0.7	-0.49** (-0.64, -0.33)	-	
			SITA (N = 71)	8.1 ± 0.9	-0.45** (-0.65, -0.25)	-	
			* p ≤ 0.001 vs. PBO				
			** p ≤ 0.0001 vs. PBO				
			FPG (mg/dL) at 12 Weeks				
			Baseline Mean ± SD	Adjusted Mean Change (95% CI)	Difference vs. PBO (95% CI)		
			PBO (N = 71)	174 ± 40	5 (-2, 12)	-	
			EMPA 1 mg (N = 71)	173 ± 40	-2 (-9, 5)	-	
			EMPA 5 mg -71	180 ± 43	-16* (-23, -9)	-	
			EMPA 10 mg (N = 71)	173 ± 36	-22* (-29, -16)	-	
			EMPA 25 mg (N = 70)	180 ± 48	-27* (-34, -20)	-	
			EMPA 50 mg (N = 70)	175 ± 35	-28* (-35, -21)	-	
			SITA (N = 71)	178 ± 44	-13** (-22, -3)	-	
			* p ≤ 0.0001 vs. PBO				
			** p ≤ 0.01 vs. PBO				
			Body Weight (kg) at 12 Weeks				
			Baseline Mean ± SD	Adjusted Mean Change (95% CI)	Difference vs. PBO (95% CI)		
			PBO	87.7 ± 15.7	-1.2	-	

## Continued

	(N = 71)		(-1.8, -0.5)	
EMPA 1 mg	90.6 ± 18.9		-1.6	-
	(N = 71)		(-2.2, -0.9)	
EMPA 5 mg	87.0 ± 14.8		-2.3*	-
	-71		(-2.9, -1.7)	
EMPA 10 mg	87.9 ± 14.4		-2.7**	-
	(N = 71)		(-3.4, -2.1)	
EMPA 25 mg	90.5 ± 16.9		-2.6**	-
	(N = 70)		(-3.2, -2.0)	
EMPA 50 mg	91.6 ± 15.8		-2.9***	-
	(N = 70)		(-3.5, -2.2)	
SITA	88.0 ± 15.0		-0.8	-
	(N = 71)		(-1.5, -0.2)	
	* p ≤ 0.01 vs. PBO			
	** p ≤ 0.001 vs. PBO			
	*** p ≤ 0.0001 vs. PBO			

95% CI = 95% confidence interval; AHA = antihyperglycemic agent; EMPA = empagliflozin; F = Female; FPG = Fasting Plasma Glucose; HbA1C = hemoglobin A1C; M = Male; MET = metformin; PBO = placebo; SD = standard deviation; SITA = sitagliptin; T2DM = Type 2 Diabetes Mellitus Patients.

#### 4. Conclusion

Considering the increasing prevalence and incidence of type 2 diabetes mellitus worldwide, there is an obvious need for effective therapeutic strategies to combat this chronic and progressive disease. The need for agents with novel mechanisms of action is becoming more and more crucial owing to the need for individualized glycemic targets and glucose-lowering therapies, concerning side effects of many current therapies, and the progressive  $\beta$ -cell function decline associated with T2DM. SGLT2 inhibitors offer this potential and recently approved canagliflozin, dapagliflozin, and empagliflozin have shown significant promise as mono- and add-on therapy to current glucose-lowering regimens that may not otherwise be providing sufficient glycemic control in T2DM patients. Short-term benefits have certainly been made clear through the variety of clinical trials performed on these drugs, however there is still a need to establish long-term safety and efficacy. The significance of the unique side effects of increased genital mycotic infections and associated adverse events must also be considered. Several other agents in this class are in phase III trials and show similar promise in their efficacy as add-on treatments.

#### Acknowledgements

We acknowledge Jennifer Heo, Sarah Jaffery, and Malay Naik for editorial review.

#### References

- [1] Centers for Disease Control and Prevention (2012) Diabetes Data & Trends. Department of Health and Human Services, Atlanta. <http://apps.nccd.cdc.gov/DDTSTRS/default.aspx>
- [2] (2014) Farxiga (Dapagliflozin) (Prescribing Information). Bristol-Myers Squibb Company, Princeton.
- [3] (2014) Jardiance (Empagliflozin) (Prescribing Information). Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield.
- [4] (2013) Invokana (Canagliflozin) (Prescribing Information). Janssen Pharmaceuticals, Titusville.
- [5] Hardman, T.C. and Dubrey, S.W. (2011) Development and Potential Role of Type-2 Sodium-Glucose Transporter Inhibitors for Management of Type 2 Diabetes. *Diabetes Therapy*, **2**, 133-145. <http://dx.doi.org/10.1007/s13300-011-0004-1>
- [6] Freeman, J.S. (2013) Review of Insulin-Dependent and Insulin-Independent Agents for Treating Patients with Type 2

- Diabetes Mellitus and Potential Role for Sodium-Glucose Co-Transporter 2 Inhibitors. *Postgraduate Medicine*, **125**, 214-226. <http://dx.doi.org/10.3810/pgm.2013.05.2672>
- [7] Rosenstock, J., Aggarwal, N., Polidori, D., Zhao, Y., Arbit, D., Usiskin, K., *et al.* (2012) Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects with Type 2 Diabetes. *Diabetes Care*, **35**, 1232-1238. <http://dx.doi.org/10.2337/dc11-1926>
- [8] Bode, B., Stenlöf, K., Sullivan, D., Fung, A. and Usiskin, K. (2013) Efficacy and Safety of Canagliflozin Treatment in Older Subjects with Type 2 Diabetes Mellitus: A Randomized Trial. *Hospital Practice*, **41**, 72-84. <http://dx.doi.org/10.3810/hp.2013.04.1020>
- [9] Cefalu, W.T., Leiter, L.A., Yoon, K.H., Arias, P., Niskanen, L., Xie, J., *et al.* (2013) Efficacy and Safety of Canagliflozin versus Glimpiride in Patients with Type 2 Diabetes Inadequately Controlled with Metformin (CANTATA-SU): 52 Week Results from a Randomised, Double-Blind, Phase 3 Non-Inferiority Trial. *The Lancet*, **382**, 941-950. [http://dx.doi.org/10.1016/S0140-6736\(13\)60683-2](http://dx.doi.org/10.1016/S0140-6736(13)60683-2)
- [10] Inagaki, N., Kondo, K., Yoshinari, T., Maruyama, N., Susuta, Y. and Kuki, H. (2013) Efficacy and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, 12-Week Study. *Diabetes, Obesity and Metabolism*, **15**, 1136-1145. <http://dx.doi.org/10.1111/dom.12149>
- [11] Lavalley-González, F.J., Januszewicz, A., Davidson, J., Tong, C., Qiu, R., Canovatchel, W., *et al.* (2013) Efficacy and Safety of Canagliflozin Compared with Placebo and Sitagliptin in Patients with Type 2 Diabetes on Background Metformin Monotherapy: A Randomised trial. *Diabetologia*, **56**, 2582-2592. <http://dx.doi.org/10.1007/s00125-013-3039-1>
- [12] Scherthaner, G., Gross, J.L., Rosenstock, J., Guarisco, M., Fu, M., Yee, J., *et al.* (2013) Canagliflozin Compared with Sitagliptin for Patients with Type 2 Diabetes Who Do Not Have Adequate Glycemic Control with Metformin Plus Sulfonylurea: A 52-Week Randomized Trial. *Diabetes Care*, **36**, 2508-2515. <http://dx.doi.org/10.2337/dc12-2491>
- [13] Stenlöf, K., Cefalu, W.T., Kim, K.A., Alba, M., Usiskin, K., Tong, C., *et al.* (2013) Efficacy and Safety of Canagliflozin Monotherapy in Subjects with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and Exercise. *Diabetes, Obesity and Metabolism*, **15**, 372-382. <http://dx.doi.org/10.1111/dom.12054>
- [14] Wilding, J.P., Charpentier, G., Hollander, P., González-Gálvez, G., Mathieu, C., Vercruysse, F., *et al.* (2013) Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Sulphonylurea: A Randomised Trial. *International Journal of Clinical Practice*, **67**, 1267-1282. <http://dx.doi.org/10.1111/ijcp.12322>
- [15] Yale, J.F., Bakris, G., Cariou, B., Yue, D., David-Neto, E., Xi, L., *et al.* (2013) Efficacy and Safety of Canagliflozin in Subjects with Type 2 Diabetes and Chronic Kidney Disease. *Diabetes, Obesity and Metabolism*, **15**, 463-473. <http://dx.doi.org/10.1111/dom.12090>
- [16] Forst, T., Guthrie, R., Goldenberg, R., Yee, J., Vijapurkar, U., Meininger, G., *et al.* (2014) Efficacy and Safety of Canagliflozin over 52 Weeks in Patients with Type 2 Diabetes on Background Metformin and Pioglitazone. *Diabetes, Obesity and Metabolism*, **16**, 467-477. <http://dx.doi.org/10.1111/dom.12273>
- [17] Burki, T.K. (2012) FDA Rejects Novel Diabetes Drug over Safety Fears. *The Lancet*, **379**, 507. [http://dx.doi.org/10.1016/S0140-6736\(12\)60216-5](http://dx.doi.org/10.1016/S0140-6736(12)60216-5)
- [18] Bailey, C.J., Gross, J.L., Pieters, A., Bastien, A. and List, J.F. (2010) Effect of Dapagliflozin in Patients with Type 2 Diabetes Who Have Inadequate Glycaemic Control with Metformin: A Randomised, Double-Blind, Placebo-Controlled Trial. *The Lancet*, **375**, 2223-2233. [http://dx.doi.org/10.1016/S0140-6736\(10\)60407-2](http://dx.doi.org/10.1016/S0140-6736(10)60407-2)
- [19] Bailey, C.J., Iqbal, N., T'joen, C. and List, J.F. (2012) Dapagliflozin Monotherapy in Drug-Naïve Patients with Diabetes: A Randomized-Controlled Trial of Low-Dose Range. *Diabetes, Obesity and Metabolism*, **14**, 951-959. <http://dx.doi.org/10.1111/j.1463-1326.2012.01659.x>
- [20] Bailey, C.J., Gross, J.L., Hennicken, D., Iqbal, N., Mansfield, T.A. and List, J.F. (2013) Dapagliflozin Add-On to Metformin in Type 2 Diabetes Inadequately Controlled with Metformin: A Randomized, Double-Blind, Placebo-Controlled 102-Week Trial. *BMC Medicine*, **11**, 43. <http://dx.doi.org/10.1186/1741-7015-11-43>
- [21] Ferrannini, E., Ramos, S.J., Salsali, A., Tang, W. and List, J.F. (2010) Dapagliflozin Monotherapy in Type 2 Diabetic Patients with Inadequate Glycemic Control by Diet and Exercise: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial. *Diabetes Care*, **33**, 2217-2224. <http://dx.doi.org/10.2337/dc10-0612>
- [22] Henry, R.R., Murray, A.V., Marmolejo, M.H., Hennicken, D., Ptaszynska, A. and List, J.F. (2012) Dapagliflozin, Metformin XR, or Both: Initial Pharmacotherapy for Type 2 Diabetes, a Randomised Controlled Trial. *International Journal of Clinical Practice*, **66**, 446-456. <http://dx.doi.org/10.1111/j.1742-1241.2012.02911.x>
- [23] Kaku, K., Inoue, S., Matsuoka, O., Kiyosue, A., Azuma, H., Hayashi, N., *et al.* (2013) Efficacy and Safety of Dapagliflozin as a Monotherapy for Type 2 Diabetes Mellitus in Japanese Patients with Inadequate Glycaemic Control: A Phase II Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. *Diabetes, Obesity and Metabolism*, **15**, 432-440. <http://dx.doi.org/10.1111/dom.12047>

- [24] Nauck, M.A., Del Prato, S., Meier, J.J., Durán-García, S., Rohwedder, K., Elze, M., *et al.* (2011) Dapagliflozin versus Glipizide as Add-On Therapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control with Metformin: A Randomized, 52-Week, Double-Blind, Active-Controlled Noninferiority Trial. *Diabetes Care*, **34**, 2015-2022. <http://dx.doi.org/10.2337/dc11-0606>
- [25] Rosenstock, J., Vico, M., Wei, L., Salsali, A. and List, J.F. (2012) Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA<sub>1c</sub>, Body Weight, and Hypoglycemia Risk in Patients with Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy. *Diabetes Care*, **35**, 1473-1478. <http://dx.doi.org/10.2337/dc11-1693>
- [26] Strojek, K., Yoon, K.H., Hrubá, V., Elze, M., Langkilde, A.M. and Parikh, S. (2011) Effect of Dapagliflozin in Patients with Type 2 Diabetes Who Have Inadequate Glycaemic Control with Glimpiride: A Randomized, 24-Week, Double-Blind, Placebo-Controlled Trial. *Diabetes, Obesity and Metabolism*, **13**, 928-938. <http://dx.doi.org/10.1111/j.1463-1326.2011.01434.x>
- [27] Wilding, J.P., Norwood, P., Tjoen, C., Bastien, A., List, J.F. and Fiedorek, F.T. (2009) A Study of Dapagliflozin in Patients with Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a Novel Insulin-Independent Treatment. *Diabetes Care*, **32**, 1656-1662. <http://dx.doi.org/10.2337/dc09-0517>
- [28] Wilding, J.P., Woo, V., Soler, N.G., Pahor, A., Sugg, J., Rohwedder, K., *et al.* (2012) Long-Term Efficacy of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Receiving High Doses of Insulin: A Randomized Trial. *Annals of Internal Medicine*, **156**, 405-415. <http://dx.doi.org/10.7326/0003-4819-156-6-201203200-00003>
- [29] Heise, T., Seewaldt-Becker, E., Macha, S., Hantel, S., Pinnetti, S., Seman, L., *et al.* (2013) Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following 4 Weeks' Treatment with Empagliflozin Once Daily in Patients with Type 2 Diabetes. *Diabetes, Obesity and Metabolism*, **15**, 613-621. <http://dx.doi.org/10.1111/dom.12073>
- [30] Ferrannini, E., Seman, L., Seewaldt-Becker, E., Hantel, S., Pinnetti, S. and Woerle, H.J. (2013) A Phase IIb, Randomized, Placebo-Controlled Study of the SGLT2 Inhibitor Empagliflozin in Patients with Type 2 Diabetes. *Diabetes, Obesity and Metabolism*, **15**, 721-728. <http://dx.doi.org/10.1111/dom.12081>
- [31] Rosenstock, J., Seman, L.J., Jelaska, A., Hantel, S., Pinnetti, S., Hach, T., *et al.* (2013) Efficacy and Safety of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, as Add-On to Metformin in Type 2 Diabetes with Mild Hyperglycaemia. *Diabetes, Obesity and Metabolism*, **15**, 1154-1160. <http://dx.doi.org/10.1111/dom.12185>